Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases

Covers the latest evidence on the commonalities of neurodegenerative disorders and metabolic disease

Grazyna Soderbom (Volume editor), Russell Esterline (Volume editor), Jan Oscarsson (Volume editor), Mark P. Mattson (Volume editor)

9780128200766, Elsevier Science

Hardback, published 29 July 2020

452 pages
22.9 x 15.1 x 2.8 cm, 0.84 kg

Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease summarizes recent developments in intervention trials in neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s, as well as increasing evidence for the overlap between drivers of metabolic and neurodegenerative disease that impact mitochondrial function and bioenergetics, and subsequently cellular function and pathophysiology. Topics covered include Brain Glucose and Ketone Utilization in Brain Ageing and Neurodegenerative Diseases; the Mitochondrial Hypothesis: Dysfunction, Bioenergetic Defects, and the Metabolic Link to Alzheimer’s Disease; the Metabolic Impact on Neuroinflammation and Microglial Modulation in Neurodegenerative Diseases, the Impact of Circadian and Diurnal Rhythms on Cellular Metabolic Function and Neurodegenerative Diseases, and much more.

1. Status and future directions of clinical trials in Alzheimer’s disease
Germán Plascencia-Villa and George Perry
2. Tracking the potential involvement of metabolic disease in Alzheimer's disease—Biomarkers and beyond
Jose A. Luchsinger and Henrik Zetterberg
3. Brain glucose and ketone utilization in brain aging and neurodegenerative diseases
Dimitrios Kapogiannis and Konstantinos I. Avgerinos
4. Disturbances in brain energy metabolism in insulin resistance and diabetes and Alzheimer's disease—Learnings from brain imaging biomarkers
Kerstin Heurling, Edvin Johansson and Antoine Leuzy
5. APOE and metabolic dysfunction in Alzheimer’s disease
Lance A. Johnson
6. Status and future directions of clinical trials in Parkinson's disease
Grazyna Söderbom
7. Involvement of GABAergic interneuron dysfunction and neuronal network hyperexcitability in Alzheimer's disease: Amelioration by metabolic switching
Mark P. Mattson
8. The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease
Russell H. Swerdlow
9. MAM and C99, key players in the pathogenesis of Alzheimer’s disease
Marta Pera, Jorge Montesinos, Delfina Larrea, Rishi R. Agrawal, Kevin R. Velasco, Irina G. Stavrovskaya, Taekyung D. Yun and Estela Area-Gomez
10. Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson’s disease genetic risk
Ria Thomas, Penelope J. Hallett and Ole Isacson
11. Endosomal-lysosomal dysfunction in metabolic disorders and Alzheimer's disease
Michael F. Almeida, Ben A. Bahr and Stephen T. Kinsey
12. Neuroinflammation, microglial activation, and glucose metabolism in neurodegenerative diseases
Paul Edison
13. The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases
Grazyna Söderbom and Bai-Yun Zeng
14. Impact of circadian and diurnal rhythms on cellular metabolic function and neurodegenerative diseases
S. Kendall Smith and Erik S. Musiek
15. The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases
Molly Braun and Jeffrey J. Iliff

Subject Areas: Neurosciences [PSAN], Neurology & clinical neurophysiology [MJN]